Intellia Therapeutics (NTLA)
21.28
-0.25 (1.16%)
Upcoming Events
Latest Headlines
Form 3 Intellia Therapeutics, For: Apr 10 Filed by: Dube Michael P
April 22, 2024 4:10 PM - SEC Filing
Form PRE 14A Intellia Therapeutics, For: Jun 12
April 16, 2024 4:11 PM - SEC Filing
Form 8-K Intellia Therapeutics, For: Apr 10
April 15, 2024 4:22 PM - SEC Filing
Form 8-K Intellia Therapeutics, For: Mar 19
March 22, 2024 9:26 AM - SEC Filing
Intellia Therapeutics (NTLA) PT Raised to $99 at Brookline Capital Markets
March 18, 2024 10:19 AM - StreetInsider
Intellia Therapeutics (NTLA) doses first patient in Phase 3 MAGNITUDE Study of NTLA-2001
March 18, 2024 7:36 AM - StreetInsider
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
March 18, 2024 7:30 AM - Globe NewsWire
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Hicks Derek
March 5, 2024 4:11 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Clark Eliana
March 5, 2024 4:11 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: BASTA JAMES
March 5, 2024 4:11 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Sepp-Lorenzino Laura
March 5, 2024 4:11 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: LEONARD JOHN M
March 5, 2024 4:11 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Goddard Glenn
March 5, 2024 4:10 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Lebwohl David
March 5, 2024 4:10 PM - SEC Filing
Form 424B5 Intellia Therapeutics,
February 26, 2024 7:04 AM - SEC Filing
Intellia Therapeutics (NTLA) PT Lowered to $32 at Goldman Sachs
February 26, 2024 5:57 AM - StreetInsider
Form 424B5 Intellia Therapeutics,
February 23, 2024 5:32 PM - SEC Filing
Form 8-K Intellia Therapeutics, For: Feb 23
February 23, 2024 5:20 PM - SEC Filing
Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'
February 23, 2024 9:27 AM - StreetInsider
Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
February 23, 2024 9:25 AM - StreetInsider
Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'
February 23, 2024 9:19 AM - StreetInsider
Canaccord Constructive on Intellia Therapeutics (NTLA), 'Key programs continue to progress on track'
February 23, 2024 7:13 AM - StreetInsider
Form S-8 Intellia Therapeutics,
February 22, 2024 4:13 PM - SEC Filing
Form 10-K Intellia Therapeutics, For: Dec 31
February 22, 2024 4:03 PM - SEC Filing
Form 8-K Intellia Therapeutics, For: Feb 22
February 22, 2024 7:46 AM - SEC Filing
Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c
February 22, 2024 7:37 AM - StreetInsider
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
February 22, 2024 7:30 AM - Globe NewsWire
Intellia Therapeutics (NTLA) PT Lowered to $24 at Baird
February 16, 2024 6:29 AM - StreetInsider
Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
February 15, 2024 3:43 PM - StreetInsider
Intellia Therapeutics (NTLA) and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024 7:34 AM - StreetInsider
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024 7:30 AM - BizWire
Wolfe Research Starts Intellia Therapeutics (NTLA) at Peerperform
February 14, 2024 4:06 PM - StreetInsider
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
February 14, 2024 7:30 AM - Globe NewsWire
Form SC 13G/A Intellia Therapeutics, Filed by: VANGUARD GROUP INC
February 13, 2024 5:12 PM - SEC Filing
Form 8-K Intellia Therapeutics, For: Jan 31
February 1, 2024 4:05 PM - SEC Filing
Intellia Therapeutics (NTLA) Announces Publication of Positive Interim Phase 1 Data for NTLA-2002
January 31, 2024 5:00 PM - StreetInsider
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
January 31, 2024 5:00 PM - Globe NewsWire
Form SC 13G/A Intellia Therapeutics, Filed by: ARK Investment Management LLC
January 29, 2024 4:01 PM - SEC Filing
Full Article List
